Dr. Vera Voronina worked for Regeneron Pharmaceuticals from 2008 until 2020, growing from a Scientist to an Associate Director of a Technology Development group. Her work focused on generation and characterization of mouse lines that produce fully human T cell receptors and antibodies. Prior to joining Regeneron she completed post-doctoral training in cell biology and signaling at the University of Washington, where she identified mechanisms underlying primary ciliary dyskinesia. Dr. Voronina obtained a PhD jointly from the National Cancer Institute and West Virginia University, and her thesis work focused on elucidation of genetic causes of anophthalmia and microphthalmia.
